All In Biotech

Drug Trial Radar · NCT02215512

Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases

A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Feb 6, 2015

Primary completion

Nov 28, 2016

Study completion Nov 12, 2020

Sponsor

Lead sponsor
EpicentRx, Inc.Industry
Sponsor type
Industry
First posted
Aug 13, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this dose-escalation study, the safety and tolerability of escalating dose levels of RRx-001 administered intravenously twice a week in subjects with brain metastases receiving whole brain radiation therapy (WBRT) will be assessed. Once a maximum tolerated dose is identified, further (up to approximately 30) participants will be recruited. The study will use MRI to monitor changes in tumor blood flow associated with RRx-001.

Conditions

  • Brain Metastases

Interventions

  • RRx-001 + WBRTDrug

    Subjects will receive a combination of RRx-001 and whole brain radiotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number, frequency and type of adverse eventsTime frame: 42 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Providence Saint John's Health Center

    Santa Monica, California

  • University of Michigan

    Ann Arbor, Michigan

  • Allegiance Health

    Jackson, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • The Cancer Institute of New Jersey (Rutgers University)

    New Brunswick, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.